Navigation Links
SaltCheck Develops First Simplified Test for Monitoring Salt Intake in People With Hypertension

BOSTON, Feb. 26 /PRNewswire/ -- SaltCheck, Inc. announced the completion of a 100 subject study demonstrating successful use of a new simplified test for monitoring sodium intake. The test, which can be used either for self-monitoring by people with hypertension, or for point-of-care testing at the physician's office, is revolutionary in providing immediate feedback on urine sodium excretion, which closely mirrors sodium intake. It involves dipstick testing, with results refined by statistical adjustments derived from a series of clinical studies.

The World Health Organization estimates there are over 600 million people globally with hypertension, and salt intake is known to affect blood pressure and/or response to blood pressure medication in most. Awareness of salt intake, and efforts to reduce salt intake are receiving increasing emphasis. The National Institutes of Health has recommended limiting intake of salt upon diagnosis of hypertension.

The studies, which were conducted at Weill Cornell Medical College, and sponsored by SaltCheck, Inc., accurately estimated sodium excretion from a simple spot check of urine. The SaltCheck test provides a snapshot of the state of sodium excretion, and also correctly indicates whether a patient's sodium excretion over a 24-hour period is low or not, with a high degree of sensitivity and specificity. Most important, it will be the first commercially-available test for assessing salt intake, and its ease of use and low cost will readily enable serial monitoring of salt intake, and of the effect of efforts to change salt intake.

The test also eliminates the two biggest drawbacks of the current testing method, which consists of collecting all urine during a 24 hour period, and sending it to a laboratory. "The standard test is frequently inaccurate because of incomplete collections, reflecting the difficulty and impracticality of collecting all urine for 24 hours. Worse, because the test is so cumbersome, very few doctors and patients ever evaluate salt intake, despite the growing and widespread awareness of its importance in managing hypertension," commented Marc Eichenberger, COO of Allied Minds, the parent company of SaltCheck.

Owing to its ease of use, suitability for serial monitoring, and accuracy of results, SaltCheck has the potential to help in the management of many millions with hypertension. Surveys suggest that physicians would embrace testing of their patients' salt intake if a convenient and inexpensive test were available. Testing could also help improve patient compliance with drug and dietary prescriptions.

"We are extremely pleased with the results from this significant study and the commercial progress to-date of the company. We very much look forward to bringing this groundbreaking test to the market to help patients and doctors worldwide in managing hypertension," added Mr. Eichenberger.

About SaltCheck, Inc. and Allied Minds, Inc.

SaltCheck is a privately-held startup company formed by Allied Minds, Inc. to commercialize a groundbreaking patient salt intake monitoring system that doesn't require laboratory facilities. The technology was originally developed at Weill Cornell Medical College by Drs. Samuel Mann and Linda Gerber, who conducted the studies reported here. For more information, please visit the SaltCheck website:

Allied Minds, Inc. is the premier seed organization for early-stage technology. The company focuses on converting academic discoveries into commercial reality by working exclusively with a network of U.S. universities and national labs. By filling the gap between government grants and traditional venture capitalists, Allied Minds focuses on funding innovations with significant transformative potential. Instead of managing funds, the company fosters early-stage companies through to success, generating value for all stakeholders. Allied Minds has a nationwide footprint with offices in Boston, Seattle, Washington, D.C. and Los Angeles, and a European presence in London, United Kingdom. Website:


Weill Cornell Medical College requires their faculty members Drs Mann and Gerber to disclose that they and Weill Cornell Medical College have a potential financial interest in the outcome of this study.

SOURCE SaltCheck, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Couples more likely to divorce if spouse develops cervical or testicular cancer
2. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
3. UCLA doctor develops new technique to treat varicose veins
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. Silverchair Learning Systems Updates and Develops New Courses
6. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
7. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
8. MIT develops thin-film micro pharmacy
9. Omron Healthcare Develops Solar-Powered Digital Blood Pressure Monitors
10. Psychologist develops post-operative care for heart patients in Bermuda
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: